BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Echo Therapeutics (ECTE) Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain


11/19/2012 9:07:54 AM

PHILADELPHIA, Nov. 19, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that Daniel Sunday has been hired as its Vice President of Manufacturing and Global Supply Chain. In this newly created position, Mr. Sunday will be responsible for creating, driving and implementing the Company's global supply chain strategy.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO)

"Dan's extensive knowledge and substantial experience in all aspects of operations across the medical device and contract manufacturing sectors will contribute to the success of Symphony's global commercialization," said Patrick Mooney, M.D., Echo's Chairman and CEO. "We are extremely pleased to welcome Dan as an integral member of Echo's management team. Adding Dan to our outstanding team will ensure we are well positioned for a successful product launch and long-term commercial strategy."

Mr. Sunday brings nearly three decades of manufacturing and global supply chain operations experience to Echo. He joins Echo from Animas Corporation, a Johnson & Johnson company, where he most recently served as Plant Manager, managing daily operations for its insulin delivery products within an FDA regulated environment. During his 12 years at Animas, Mr. Sunday developed and implemented supply chain policies, objectives, and initiatives aligned to company strategies. He has a track record of being a results-driven business leader with proven expertise in directing all aspects of global supply chain operations in regulated environments while sustaining a focus on quality and efficiency. He also championed the development of a high performance sixty plus member supply chain organization. Prior to Animas, Mr. Sunday held manufacturing and supply chain positions at Kulicke & Soffa Industries, Efector Inc., Porter Instrument Company, and Ethicon Inc. Mr. Sunday has a deep knowledge of manufacturing operations and FDA and ISO regulatory standards. He received his B.S. degree in Industrial and Management Engineering from Widener University and an MBA from LaSalle University.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system. Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care. Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:

Christine H. Olimpio

Director, Investor Relations and Corporate Communications

(215) 717-4104

colimpio@echotx.com


Connect With Us:

- Visit our website at www.echotx.com

- Follow us on Twitter at www.twitter.com/echotx

- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES